Posts

AstraZeneca pays Sino $200M upfront, up to $1.9B for COPD challenger to Merck’s Ohtuvayre

on

Zymeworks agrees to acquire Theravance Biopharma for $929 million in cash plus contingent consideration

on

Sanofi's Bispecific Scores Double Respiratory Phase 2 Wins but Flunks Eczema Study

on

AstraZeneca's Tozorakimab Achieves Phase 3 Success in Broader COPD Population

on

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

on

Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial

on

GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China's Hengrui Pharma

on

Merck Makes $10B Acquisition of Verona Pharma to Bolster Respiratory Portfolio

on

Sanofi, Regeneron's IL-33 Drug Fails One of Two COPD Studies, Casting Doubt on FDA Approval Timeline

on

Sanofi, Regeneron's IL-33 Drug Fails One of Two COPD Studies, Casting Doubt on FDA Approval Timeline

on